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Abstract
Background: Salbutamol abuse detection by athletes is based on a urinary upper threshold defined by the World
Anti-Doping Agency (WADA). However, this threshold was determined in healthy, untrained individuals and after a
dose of salbutamol inhaled that might not really mirror the condition of asthmatic athletes and the experts’s
guidelines for asthma management. We aimed to revise this threshold in accordance with recommended clinical
practice (that appear to be different from the actual WADA recommendation) and in exercise conditions.
Methods: For the present open-label design study, we included 12 trained male cyclists (20 to 40 y/o) with asthma.
Differently from the previous pharmacokinetic study supporting the actual salbutamol urinary upper threshold, we
decided to administer a close to recommended clinical practice daily dose of 3x200 μg.d−1 inhaled salbutamol
(instead of 1600 μg.d−1 as authorized by the anti-doping policy). Urine salbutamol concentration was quantified by
liquid chromatography-tandem ion trap mass spectrometry and corrected for urine density, at rest and after a
90-min cycling effort at 70-80 % of the maximal aerobic power.
Results: The maximum urine salbutamol concentration value peaked after the cycling effort and was 510 ng.mL−1.
That is twice lower than the actual WADA threshold to sanction salbutamol abuse, this “legal” threshold being
based on pharmacokinetic data after a daily dose that is 8 fold the total dose sequentially administrated in our
study. Considering its 95 % confidence interval, this threshold value could be more stringent.
Conclusion: By using conditions in accordance with the experts’ clinical and safety guidelines for asthma
management in athletes undergoing an intense exercise bout, our study suggests that the urine salbutamol
concentration threshold could be lowered to redefine the rule supporting the decision to sanction an athlete for
salbutamol abuse.
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Background
Although the efficacy of anti-doping controls has im-
proved, fighting against doping remains a priority in
sport policy. As exposed in the Final Revised 2015
World Anti-Doping Code edited by the World Anti-
Doping Agency (WADA), prevention (ethic and health
public aspects), detection (doping control) and sanction
are key aspects of anti-doping policies [1].
The WADA list [1] of prohibited substances is accepted
worldwide and has been adopted by the International
Olympic Committee (IOC). For instance, beta2-adrenergic
receptor agonist (BA) are listed as banned substances
because they can be used for athletic performance
enhancement [2–4]. However, BA are listed as one the
medications to prevent and treat the symptoms of
exercise-induced bronchospasm (EIB) among athletes,
with or without a known diagnosis of asthma. Accord-
ingly, athletes are sanctioned for BA use except when
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taking salbutamol, salmeterol and formoterol, for medical
reasons, by inhalation, at a maximum dose and the urine
concentration must not exceed a threshold value for sal-
butamol and formoterol.
Salbutamol is one of the most popular short-acting BA
(SABA) used to relieve asthma symptoms. This medica-
tion can prevent asthma symptoms and should be taken
10 to 15 min before exercise. It will help prevent symp-
toms for up to four hours. Salbutamol can also be used
to treat and reverse the symptoms of EIB. Based on the
current WADA guidelines, the SABA salbutamol can be
prescribed up to 1600 μg per 24 h. According to recent
expert clinical guidelines from Global Initiative for
Asthma (GINA) recommendations [5] and the American
Thoracic Society (ATS) Clinical practice guidelines [6],
SABAs can be prescribed during sport practice to prevent
EIB, just before exercise: inhaled doses of 200–400 μg
could be inhaled just before exercise as suggested by Tan
et al. [7]. In addition, doses between 400 to 800 μg can be
inhaled up to the 2nd or 4th hour of asthma attack, and
then repeated if necessary but this situation should be
considered with caution among athletes because acute
and intense exercise triggers EIB [8]. Anyway, inhalation
of 1600 μg is neither encouraged in a day for prevention
of EIB. To justify the WADA daily upper limit of
1600 μg.d−1 for inhaled salbutamol (a limit that is 2 · 5 fold
higher than the limit proposed by experts in asthma),
Dickinson et al. suggested that this limit was proposed by
WADA to take into account the fact “that asthmatic ath-
letes are often instructed to use their inhaler on an as
needed basis that could be interpreted by the athletes as a
clearance to inhale unlimited amounts of salbutamol to
combat respiratory symptoms” [9]. However, this assertion
is in contradiction with experts guidelines cited above
(GINA and ATS recommendations) and with recommen-
dations published in a very recent review published by
Boulet et al. [10]. According to these guidelines and
recommendations, SABAs should be used only as-needed
at the lowest dose and frequency required to prevent
eventual tachyphylaxis. Moreover, this assertion could be
discussed based on clinical practice and ethical consider-
ations. Indeed asthma requiring such high BA doses
should not be compatible with current high level physical
and sports performance if we consider that the high levels
of ventilation sustained in such exercise conditions are
identified as triggers for EIB [2].
A second question concerns the maximum urine con-
centration of salbutamol accepted in the case of “thera-
peutic prescription”. Historically, salbutamol was the first
bronchodilatator listed in the international anti-doping list
according to a urinary threshold for sanction. According
to Dickinson [9], this current WADA urinary threshold
(1000 ng.mL−1) is based on data published in 2000 by
Berges et al. [11]. In this study, non-asthmatic recreational
swimmers inhaled 1600 μg salbutamol and then the urine
salbutamol concentration was determined at rest. This
study, like all the other studies consecutively published
with the objective of assessing salbutamol pharmacokinet-
ics after inhalation or oral administration (Table 1), was
not conducted in asthmatic competitive athletes and sam-
ples were not collected during exercise. Therefore, it can
be concluded that no study was conducted in laboratory
conditions mirroring the exercise conditions experienced
by asthmatic athletes. In addition, none of the studies on
salbutamol was performed using an adjusted and clinical
relevant dose of salbutamol to manage asthma or EIB in
athletes (i.e., a dosing regimen in accordance with experts’
recommendations in the field).
Accordingly, the objective of our study was to assess the
pharmacokinetics of inhaled salbutamol 1) in asthmatic
athletes and 2) after a single bout of intense exercise and
3) after a recommended (by experts in asthma but not
according to the WADA list) dosing regimen of inhaled
salbutamol for athletes undergoing an intense exercise
bout (i.e. 200 μ.d−1 of salbutamol three times per day).
Methods
Study design
This study used an open-label design. All participants
visited our laboratory four times. During the first visit
the diagnosis of asthma was confirmed by direct bron-
chial provocation test with methacholine chloride. Dur-
ing the second visit, the endurance capacity was assessed
to determine the intensity of the exercise session. Then,
two consecutive sessions were dedicated to assessing sal-
butamol pharmacokinetics in plasma and urine at rest
(rest pharmacokinetic session, D1) and, the next day,
during a bout of intense endurance exercise (exercise
pharmacokinetic session, D2). Participants were asked to
stop their current anti-asthmatic treatment three days
before the rest pharmacokinetic session and to inhale
salbutamol three times per day (see the Medications sec-
tion; study design is presented in Fig. 1).
The study protocol was approved by the scientific
committee of the French Anti-Doping Agency and by
the Toulouse hospital ethics committee (agreement n°
0830103).
Participants and lung function assessment
This study included 12 men, aged between 20 and
40 year. They were trained cyclists and were enrolled in
the study if they practiced eight hours or more of cycling
per week. All were enrolled in competition. All were
non smokers. All experienced clinical symptoms of
asthma according to GINA classification, including EIB
and all had been using a SABA on demand for at least
one year. All the patients used SABA at least one time
during the two weeks before their enrollment in the study.
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Patients reported they used SABA some days before exer-
cise when they observed a “short breath” compared to
other days. No one had ever had a severe asthma attack.
In the absence of exacerbations, our cohort was defined as
a mild asthma cohort.
Only men were studied in this preliminary study to ex-
clude any pharmacological variation related to menstrual
hormonal disturbances in women.
Written informed consent was obtained by all subjects.
The methacholine challenge test was used to confirm
the diagnosis of asthma and a negative challenge test
was used to exclude the diagnosis of asthma. All the par-
ticipants were asked to stop their SABA at least 48 h be-
fore lung function assessment [12]. Pulmonary function
testing was done using a whole body plethysmograph
(Jaeger Master Screen Body™ Plethysmograph). The
methacholine challenge test was performed using the
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Fig. 1 Study design
Table 1 Published studies on the pharmacokinetics of inhaled salbutamol (updated on the 31st July 2014)
Physical activity Asthmatic status Salbutamol inhaled dose Rest or exercise Exercise intensity Sample size
Anderson1998 [26] Untrained Healthy 1 × 180 μg Rest 10
Berges2000 [11] Trained Asthmatic 1 × 200 μg Rest 15
Healthy 4 × 400 μg 17
Pichon2006 [27] Trained Healthy 3 × 200 μg Rest 10
Sporer2008 (1) [28] Trained Healthy 1 × 200 μg Exercise
(and Rest)
Cycling time 30
and 1 × 400 μg
and 1 × 800 μg
Sporer2008 (2) [29] Untrained Healthy 1 × 200 μg Rest 8
Elers2010 [30] Untrained Asthmatic 1 × 200 μg Rest 10
Elers2011 [31] Untrained Asthmatic 4 × 400 μg Rest 10
Healthy 10
Elers2012 [19] Trained Asthmatic 1 × 800 μg Rest 10
Healthy





and 1 × 1600 μg
Theoretical “Link-field study” Trained Asthmatic Preventive




Bold data identify conditions that we consider as optimal based on a rigorous clinical and scientific approach
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(APS, Viasys) [13]. The cumulative dose of methacho-
line provoking a 20 % decrease (PD20) in the forced
expiratory volume in 1 s (FEV1) was calculated to
confirm the participant’s asthmatic status. According
to the ATS guidelines, the PD20 threshold was set at
1600 μg [12, 13].
Endurance exercise testing and endurance exercise
during the exercise pharmacokinetic session
The participant’s endurance capacity was assessed to
check their fitness level. To this aim, maximal graded ex-
ercise tests were conducted in our laboratory. Subjects
used their own bicycle and equipment. The power output
was assessed using the Power Tap mobile cycling ergom-
eter® (Cycle Ops, Madison, WI, USA) [14]. During the test,
oxygen consumption (VO2, expressed in L.min
−1 and
mL.min−1.kg−1) was assessed using an Oxycon Pro ergos-
pirometer® (Erich Jaeger, Viasys Healthcare, Germany).
The VO2max and its corresponding power, the maximal
aerobic power (MAP) were measured.
During the exercise pharmacokinetic session, subjects
performed a 90 min bout of endurance exercise in the
same general conditions as for the MAP determination
(i.e., on their own bicycle and power output was
assessed by using the Cycle OPS Power Tap™ system).
After 10-min warm up at 60 % of their MAP, partici-
pants were asked to exercise at 70–80 % of their MAP
for the last 80 min.
Medications
At enrolment, all participants declared salbutamol use
on demand (2 × 100 μg.d−1 just before exercise or in case
of asthma symptoms). None of them reported salbuta-
mol dose higher than 400 μg.d−1 over the past year be-
fore enrolment in this study. Four declared a treatment
to control asthma (see Subjects in the Results section).
All subjects had to abstain from using any medicine, in-
cluding SABA, 2 weeks before the pharmacokinetic
session.
The protocol of the study is detailed in Fig. 1. At least
one week before the rest pharmacokinetic session (D1,
Fig. 1), all participants received a full salbutamol aerosol
inhaler and a valve holding chamber. To follow salbuta-
mol consumption, the weight of two puffs was arbitrarily
defined by weighing each inhaler before and after 4 puffs
and the weigh difference divided by two.
Each participant received written and oral instructions
to inhale salbutamol three times a day (2 puffs/each
time). Participants were asked to inhale 200 μg salbuta-
mol three times daily scheduled for 3 consecutive days
(D1-3, D1-2, D1-1). This scheme of salbutamol inhal-
ation was reproduced on the 4th consecutive day de-
signed as the rest pharmacokinetic session (D1). From
D1-3 to D2 (exercise pharmacokinetic session, next day
after D1), salbutamol was administered in the same con-
ditions. Participants were asked to bring back the inhaler
at D2. At the end of the exercise pharmacokinetic ses-
sion, the inhaler was weighted again and the difference
in weight was used to control salbutamol administration.
Despite subjects enrolled in the study were not under
a daily salbutamol inhalation treatment scheme, regular
and pre-exercise inhalation of salbutamol were proposed
for the study to mimic a treatment scheme by SABA
that might be proposed as a part of the global treatment
(SABA and addition of a controller) for more severe
asthmatics. The dose of 200 μg for each of the three
daily inhalations was defined because this dose is close
to the maximal dose recommended before exercise
(400 μg) while this dose would be usual for mild asth-
matic subjects.
Urine sample
During the rest and exercise pharmacokinetic sessions,
urine was collected at baseline (T0) and at 30 min, 2 h
(i.e., just after the 90-min intense exercise in the case of
the exercise pharmacokinetic session), 4 h and 6 h after
the first dose of 200 μg of salbutamol. Participants were
encouraged to drink water regularly to favour urine ex-
cretion for sampling. Night urine was collected at home
by the participants in a dark container and delivered to
our laboratory kept out from light. For each time point,
the total urine sample volume was recorded and two
30 mL aliquots were stored at −80 °C until analysis.
Bioanalytical analysis of urine samples
Urine samples were pre-treated according to the current
procedures used by anti-doping laboratories to detect
total salbutamol (i.e., salbutamol and its glucuronide)
[15]. Salbutamol-D9 was used as internal standard. After
extraction from urine by solid-phase extraction, salbuta-
mol concentration was assessed by hydrophilic inter-
action chromatographic and liquid chromatography with
atmospheric pressure chemical ionization mass spec-
trometry. Bioanalytical analyses were performed at the
Pharmacokinetic and Toxicological Laboratory of Tou-
louse Hospital (France). This laboratory is accredited by
COFRAC, the French accreditation body, under the
European norm n°1589.
Urine salbutamol concentration values were corrected
to the urine density, as previously recommended [9].
The maximum urine concentration of salbutamol for
each participant and for each experimental session was
defined as the highest value for each session (Cumax-rest
and Cumax-ex, in ng.mL
−1, were labeled for resting and
exercising session respectively). For each participant, the
highest of these values was defined as the Cumax (the
maximum urine concentration of salbutamol that could
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be detected for each participant, regardless the specific
rest or post-exercise conditions).
Statistical analysis
Sample size calculation to fit well-powered analysis in
order to test our main hypothesis was based on the sal-
butamol concentration distribution in urine samples de-
scribed by Tomlinson et al. [16] and with the aim of
computing the confidence interval for salbutamol con-
centration in urine according to the general methodo-
logical recommendations by Gardner and Altman [17]
and the recommendations edited by an Expert Panel on
Theory of Reference Values from the International Fed-
eration of Clinical Chemistry and Laboratory Medicine
[18]. We thus needed to include 12 subjects to assume a
precision of 85 and a 95 % confidence level for the confi-
dence interval. The confidence intervals of salbutamol
distribution were computed for 95 and 99 % confidence
levels.
For bivariate analysis, the normality of distribution of
quantitative variables was tested using the skewness and
kurtosis test (sktest). As some variables differed from the
normal distribution, bivariate analysis was performed
using the Wilcoxon matched-pairs ranks test or the
Friedman’s test for repeated variables. Bivariate analysis was
carried out with a significance level <0 · 05. For repeated
variables, a Bonferroni adjustment of this significance level
was performed to conclude on the significance of the corre-
sponding multiple comparisons (corresponding to multiple
time points).
All statistical analyses were performed with the Stata
6 · 0 software (Stata Corporation, College Station, TX).
Results
Subjects
Twelve subjects (mean age: 29 years ± 8 · 6 SD) were re-
cruited. Baseline lung function assessed by whole-body
plethysmography was in the normal range for all the
ubjects (Table 2). Mean PD20 was 587 μg (±535 SD).
Functional aerobic assessment (VO2max, MAP and max-
imum heart rate) and the mean power sustained during
the exercise pharmacokinetic session are presented in
Table 3. According to the ATS categorization of bronchial
hyper-responsiveness (BHR), four participants (33 · 3 %)
had moderate to severe BHR, two (16 · 7 %) had mild BHR
and six (50 %) were borderline. Four subjects declared a
treatment to control asthma: 10 mg.d−1 montelukast
(n = 1), 50 μg.d−1 salmeterol + fluticasone (n = 1), 12 μg.d−1
formoterol (n = 1) or 12 μg.d−1 formoterol + budeno-
side (n = 1). As required, these subjects stopped their
standard treatment 2 weeks before the first pharma-
cokinetic session (D1).
All the subjects practiced cycling at competitive level
and were well-trained endurance athletes as indicated by
their VO2max and MAP/kg values.
Urine density
As participants were encouraged to drink water ad libi-
tum to ensure diuresis (required for urine sampling),
urine density significantly decreased from the beginning
to the end of each session (Fig. 2).
Salbutamol urinary concentration
Figure 3a and b present the distribution of salbutamol
concentration in urine during the rest and exercise ses-
sions, respectively. Table 4 presents the distribution of
Cumax-rest, Cumax-ex and Cumax and their confidence
interval. Cumax was observed in ten participants during
the exercise session and in nine after the exercise bout.
The maximal concentration was measured at 2:00 pm
(i.e., 4 h after the exercise bout). Based on the upper
value of the 95 and 99 % confidence intervals, the
threshold value of urine salbutamol for anti-doping con-
trol could be stricter, at 327 · 7 and 372 · 4 ng.mL−1
respectively.
Discussion
One could argue that there is no need to change the
rules but rather to educate athletes, coaches and the
health care providers who care about the proper use of
SABAs rather than to prevent athletes from participat-
ing. However, sanction against cheaters remains a key
point to fight against doping in sport and we need to im-
prove the judgment criteria before adopting any disciplin-
ary sanction against an athlete. By using conditions in
accordance with the experts’ clinical and safety guidelines
for asthma management in athletes undergoing an intense
exercise bout, our study demonstrates that the urine sal-
butamol concentration threshold could be lowered to re-
define the rule supporting the decision to sanction an
athlete for salbutamol abuse. Under a minimal inhaled sal-
butamol dose regimen, our study demonstrates that a
urine salbutamol concentration threshold of 507 ng.mL−1
could be used to redefine the rule supporting the decision
to sanction an athlete for salbutamol abuse. This threshold
is very far from the actual WADA threshold defined for a
Table 2 Distribution of baseline respiratory characteristics of the
subjects (n = 12 male participants)
Minimum Median Maximum Mean SD
TLC 99 115 133 116 12 · 0
Forced vital capacity 97 118 130 117 11 · 6
FEV1 93 110 125 110 9 · 1
FEV1/FVC ratio 75 78 92 79 6 · 7
PD20; μg 50 535 1500 587 535
Abbreviations: TLC total lung capacity, FVC forced vital capacity, FEV1 one-
second forced expired volume, FEV1/FVC ratio Tiffeneau-Pinelli index. Data for
TLC, FVC, FEV1 and FEV1/FVC ratio are % of the corresponding predicted value
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not recommended inhaled salbutamol dose. Even a “statis-
tically” more stringent threshold could be proposed if
anti-doping instances planned to consider the upper limit
of the 99 % confidence interval of salbutamol concentra-
tion in urine, and not the absolute maximum value de-
tected. Our proposal to implement a new threshold is
supported by methodological points supporting scientific
based bases for anti-doping policy. However, this proposal
is also closely related to some other methodological points
that make our proposal too conservative to be applied for
the heterogeneous population of asthmatic athletes.
Recently, Elers et al. highlighted methodological con-
cerns that should be taken into account in scientific
studies to support anti-doping policies against salbuta-
mol abuse. Salbutamol dosing regimen, athletic status
and testing conditions (rest/exercise) were previously
shown to influence the pharmacokinetics of inhaled sal-
butamol [19]. This methodological concern was also
stressed by the Joint Task Force of European Respiratory
Society and the European Academy of Allergy and
Clinical Immunology: “Although treatment of EIB has
been extensively studied in asthmatic subjects, it was
not so in athletes with EIB and it is not known whether
athletes with EIB respond similarly to subjects with clas-
sical allergic or nonallergic asthma” [20]. Such a meth-
odological defect can also be highlighted in recent
studies supporting the WADA restrictions to detect an
abuse of inhaled formoterol according to formoterol
concentration in urine [21]. Our study is the first to fol-
low this new methodological approach as asthmatic and
trained subjects were tested during a bout of intense exer-
cise. Our study could have been done in controls subjects
defined as non-asthmatic athletes to clearly identify the
impact of the asthmatic status on salbutamol pharmacoki-
netic in urine but we were limited by organizational con-
ditions. Elers tried to give an answer to this question after
administration of a single high inhaled dose of salbutamol
(800 μg) [22]. However he selected nonathletic subjects as
controls and despite he found no influence of asthma on
urine salbutamol concentration, this question remains
Table 3 Distribution of the results of functional aerobic assessment of the subjects (n = 12 male participants; VO2max: maximal
oxygen uptake; MAP: maximal aerobic power; SD: standard deviation)
Minimum Median Maximum Mean SD
VO2max; mL.min
−1 2800 3800 4700 3858 340
VO2max; mL.min
−1.kg−1 41 59 67 57 8 · 4
MAP; watts 210 305 340 294 40
MAP/weight; watt.kg−1 3.3 4.4 5.1 4.3 0 · 6
Maximum heart rate; beats.min−1 177 192 214 193 9 · 9
Mean power during exercise session; watts 160 225 250 215 31 · 6














Time effect during rest session (Friedman test): p<0.05
Time effect during exercise session (Friedman test): p<0.05
Fig. 2 Urine density variation during the rest (dark grey columns) and exercise (light grey columns) pharmacokinetic sessions. Stratified on rest or
exercise session, repeated measures were assessed using the Friedman’s test: p <0.05 for the time variation of urine density during rest and
exercise sessions
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unresolved to implement some scientific data that could
be useful to enhance specificity of the detection of salbuta-
mol abuse in asthmatic but also nonasthmatic athletes.
Moreover, urine density correction of urine salbutamol
concentration must be considered to minimize the effect
of this biological condition on the anti-doping judgment
criteria [19]. While this correction was not applied to
urine salbutamol concentration proposed in the article
by Berges et al. [11] that was used to define the actual
upper threshold in the WADA prohibition list, we con-
sidered this potent bias and we corrected the urine sal-
butamol concentration for urine density. This correction
is of interest to take into account the state of hydration
because dehydration alters the urine specific density, for
example during intense and prolonged exercise, thus fa-
voring an overestimation of urine salbutamol [9].
According to these two methodological points, our
study mirror field sports practice and it could help to
implement some required medical and scientific based
bases for doping control management [23].
The urine concentration threshold derived from our
study after a daily minimal dose of inhaled salbutamol to
prevent EIB (3 × 200 μg) is twice lower than the actual
threshold of 1000 ng.mL−1 proposed in the WADA pro-
hibited list to sanction salbutamol abuse. However, this
“legal” threshold is based on pharmacokinetic data after
Rest session Exercise session
Rest session Exercise session
a
b
Fig. 3 a Salbutamol urine concentration (ng.mL−1) before (dark grey columns) and after correction (light grey columns) for urine density during
the rest pharmacokinetic session. Bivariate comparisons (Wilcoxon sign rank test) between corrected and uncorrected time-stratified values.
Bonferroni correction of the significance level: * p < 0.01. b Salbutamol urine concentration (ng.mL−1) before (dark grey columns) and after
correction (light grey columns) for urine density during the exercise pharmacokinetic session. Bivariate comparisons Wilcoxon (sign rank test)
between corrected and uncorrected time-stratified values. Bonferroni correction of the significance level: *p < 0.01
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a daily dose of 1600 μg inhaled salbutamol, i.e. 8 fold the
total dose sequentially administrated in our study. Des-
pite regular daily chronic use of salbutamol as a control-
ler is not recommended by current guidelines, we justify
the three times daily inhalation of salbutamol scheduled
for the present study to prevent asthma symptoms in
the four patients who declared a daily treatment to con-
trol asthma. These patients were asked to abstain from
using this treatment 2 weeks before the pharmacokinetic
session to avoid a potent influence of such treatments
on salbutamol kinetic, as previously suggested for in-
haled corticosteroids for example [24]. The dosing regi-
men was justified to ensure homogeneity of the
pharmacological condition proposed in all volunteers.
After such a preliminary study, we highlight that influ-
ence of a treatment to control asthma on inhaled salbu-
tamol kinetic in exercise condition and in asthmatic
athletes would be of interest to optimize sensitivity and
specificity of salbutamol abuse detection in sport field
conditions.
At the present time, experts’ guidelines for EIB do not
explicitly state an optimal or minimal dose of salbutamol
but ATS EIB guidelines do cite a reference which states
that a patient should be instructed to use two (200 μg)
to four (400 μg) puffs of an inhaled SABA 30 to 60 min
before exercise [7]. Thus, considering that more severe
asthmatics undergoing very intense exercise for pro-
longed periods might require additional doses of salbuta-
mol (i.e. 4 total puffs, 400 μg) before exercise, we are
aware that our pharmacokinetic data on salbutamol
urine concentration are conservative for implementation
as a threshold for anti-doping legacy. After 400 ug in-
haled salbutamol, the resulting salbutamol urine concen-
tration could have been higher than the Cumax reported
in our study. However, we can argue that we selected
the lowest dose recommended by experts in respect to
the corresponding asthma severity of the patients from
our study. Moreover, even if we had considered the
highest dose proposed by clinical experts (400 μg), this
dose would have been very far from the maximal inhaled
dose of salbutamol authorized by the WADA list
(1600 μg) and our clinical based approach questions
about ethical and medical safety of the very high dose of
inhaled salbutamol authorized by WADA. Indeed, we
kept in mind that regular use of BAs can lead quickly to
tolerance (tachyphylaxis), reduction of their bronchopro-
tective effect [2, 20] and that high metrics of salbutamol
use are supposed to be good markers of current asthma
control, risk of future severe exacerbations and increased
risk of future extreme salbutamol overuse [25]. We
could have evaluated the beneficial and adverse effects
of the daily regular minimal dose of salbutamol inhaled
but the design of our study did not evaluate these effects
of salbutamol use as a basis for determining a threshold
to detect inhaled salbutamol abuse. Thus, one being not
able to exclude that adverse effects associated with high
inhaled dose of salbutamol are related to either more se-
vere asthma or an adverse response to SABA, we ques-
tioned about ethical and medical safety of a very high
inhaled salbutamol dose (like 1600 μg.j−1) as a treatment
scheme in athlete while the athlete is exposed to hyper-
ventilation during intense and prolonged exercise, a po-
tent condition for asthma occurrence. Sports practice
should not be exempted from avoiding common factors
associated with asthma exacerbation, such as allergens
and pollutants for allergic asthma, but also hyperventila-
tion of cold and dry air for EIB, especially when high
dose of inhaled salbutamol could be “required”. This
assertion could prevent athletes to inhale high doses of sal-
butamol, not “inadvertently” for doping, but “intentionally”
in respect to the safety of medical and environmental con-
siderations. However, in the case of asthma crisis, a high
dose of salbutamol could be inhaled by athletes in a day, up
to 1600 μg as authorized by WADA. If the crisis occurs out
of competition, this high dose might be acceptable because
it could be associated with the control of the environmental
conditions, particularly avoidance of ventilatory conditions
that triggers EIB. Under this medical consideration, we sug-
gest to consider that anti-doping legacy to detect salbuta-
mol abuse could be based on two salbutamol urine
concentration, one that could apply out of competition (a
high dose of inhaled salbutamol could be authorized) and
one that could apply during a competition (a high dose of
inhaled salbutamol wouldn’t be authorized).
A last point supporting the conservative aspect of our
study is related to the methodological choice that limited
the study to men. This choice was due to multiple
pharmacological variations in women related to men-
strual cycle. Like us, most of the previous studies to as-
sess the pharmacokinetic of salbutamol were selectively
Table 4 Distribution of the urine density corrected maximum
urine concentration of salbutamol at rest (Cumax-rest), after the
acute exercise bout (Cumax-ex) and regardless these specific
rest or post-exercise conditions (highest of these specific values
for each participant, Cumax)
Cumax-rest Cumax-ex Cumax
ng.mL−1 ng.mL−1 ng.mL–1
Minimum 46 · 9* 47 · 4 66 · 0
Median 134 · 7* 116 · 4 127 · 2
Maximum 276 · 7* 507 · 2 507 · 2
Mean 144 · 6 208 · 9 218 · 8
Standard deviation 74 · 7 179 · 4 171 · 3
95 % CI 94 · 4 – 194 · 7 94 · 9 – 322 · 8 110 · 0 – 327 · 7
99 % CI 73 · 2 – 215 · 6 48 · 1 – 369 · 7 65 · 2 – 372 · 4
95 % CI: 95 % Confidence Interval. *Wilcoxon test between rest and exercise
values: p = 0.04
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conducted only in men. The study supporting the actual
WADA urine salbutamol concentration threshold is one
of these studies. Thus, future studies should target a fe-
male cohort of asthmatic athletes to implement the re-
sults to all asthmatic athletes.
Conclusion
Based on medical considerations and methodological con-
cerns, our study provides some evidence about the need to
revise the actual WADA maximum inhaled salbutamol
dose authorized and the urine salbutamol concentration
threshold used to detect and sanction salbutamol abuse in
athletes. Our revised urine salbutamol concentration
threshold is based on medical evidence on the recom-
mended daily inhaled dose of salbutamol and dosing regi-
mens. In the case of an asthma attack or in the presence of
recurrent symptoms, the dose of inhaled salbutamol could
be increased but we argue that athletes should also be ex-
cluded from risky situations for EIB, like hyperventilation
that is common during competition. Accordingly, we
propose to consider that further studies should be planned
to define the upper confident threshold of salbutamol con-
centration in urine in asthmatic athletes, in competition
and out of competition, after inhalation of an upper limit-
low dose (400 μg) or a high dose (1600 μg) salbutamol.
Notwithstanding the pharmacokinetic dimension of the
problem, WADA prohibited list should also base the recom-
mendations on the maximum daily dose of inhaled salbuta-
mol on best practice approaches for asthma management.
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